ArticleScientific reports2022

Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy.

Apurva Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.